Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNINE Exposure and Inhibitor Monitoring in Hemophilia B
NCT01128881Phase 4Completed
- Sponsor
- Takeda
- Start
- May 2010
- Primary completion
- Aug 2012
- Modality
- Replacement Enzymes
- Countries
- 10
01
Overview
Phase 4, open-label, single-arm trial of coagulation factor ix in hemophilia B (HB), sponsored by Takeda. Primary endpoint: Hemostatic Efficacy at 28 months. Started May 2010; status: completed.
02
Drugs
coagulation factor ix
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01128881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01128881.